- Home
- EXAS vs GLOB Comparison
EXAS vs GLOB Comparison
Compare EXAS & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- GLOB
- Stock Information
- Founded
- EXAS 1995
- GLOB 2003
- Country
- EXAS United States
- GLOB Luxembourg
- Employees
- EXAS N/A
- GLOB N/A
- Industry
- EXAS Medical Specialities
- GLOB EDP Services
- Sector
- EXAS Health Care
- GLOB Technology
- Exchange
- EXAS Nasdaq
- GLOB Nasdaq
- Market Cap
- EXAS 12.3B
- GLOB 8.7B
- IPO Year
- EXAS N/A
- GLOB 2014
- Fundamental
- Price
- EXAS $71.05
- GLOB $215.44
- Analyst Decision
- EXAS Strong Buy
- GLOB Buy
- Analyst Count
- EXAS 13
- GLOB 19
- Target Price
- EXAS $79.00
- GLOB $228.42
- AVG Volume (30 Days)
- EXAS 1.4M
- GLOB 453.5K
- Earning Date
- EXAS 11-05-2024
- GLOB 11-14-2024
- Dividend Yield
- EXAS N/A
- GLOB N/A
- EPS Growth
- EXAS N/A
- GLOB 10.97
- EPS
- EXAS N/A
- GLOB 3.83
- Revenue
- EXAS $2,612,011,000.00
- GLOB $2,284,526,000.00
- Revenue This Year
- EXAS $15.53
- GLOB $17.51
- Revenue Next Year
- EXAS $13.78
- GLOB $15.59
- P/E Ratio
- EXAS N/A
- GLOB $57.16
- Revenue Growth
- EXAS 13.54
- GLOB 19.01
- 52 Week Low
- EXAS $40.62
- GLOB $151.68
- 52 Week High
- EXAS $79.62
- GLOB $251.50
- Technical
- Relative Strength Index (RSI)
- EXAS 55.81
- GLOB 60.94
- Support Level
- EXAS $68.61
- GLOB $215.50
- Resistance Level
- EXAS $71.49
- GLOB $224.47
- Average True Range (ATR)
- EXAS 1.91
- GLOB 5.23
- MACD
- EXAS -0.34
- GLOB -0.04
- Stochastic Oscillator
- EXAS 50.41
- GLOB 65.65
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
About GLOB Globant S.A.
Globant SA is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the U.S. and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.